CA2994518C - METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN - Google Patents

METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN

Info

Publication number
CA2994518C
CA2994518C CA2994518A CA2994518A CA2994518C CA 2994518 C CA2994518 C CA 2994518C CA 2994518 A CA2994518 A CA 2994518A CA 2994518 A CA2994518 A CA 2994518A CA 2994518 C CA2994518 C CA 2994518C
Authority
CA
Canada
Prior art keywords
synuclein
alpha
antibody
methods
phosphorylated alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2994518A
Other languages
English (en)
French (fr)
Other versions
CA2994518A1 (en
Inventor
Robin Barbour
Lynn R Zieske
Sarah Hamren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CA2994518A1 publication Critical patent/CA2994518A1/en
Application granted granted Critical
Publication of CA2994518C publication Critical patent/CA2994518C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
CA2994518A 2015-08-25 2016-08-25 METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN Active CA2994518C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209800P 2015-08-25 2015-08-25
US62/209,800 2015-08-25
US201662297777P 2016-02-19 2016-02-19
US62/297,777 2016-02-19
PCT/IB2016/055088 WO2017033152A1 (en) 2015-08-25 2016-08-25 Methods for detecting phosphorylated alpha-synuclein

Publications (2)

Publication Number Publication Date
CA2994518A1 CA2994518A1 (en) 2017-03-02
CA2994518C true CA2994518C (en) 2025-05-06

Family

ID=56926235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2994518A Active CA2994518C (en) 2015-08-25 2016-08-25 METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN

Country Status (9)

Country Link
US (3) US10852309B2 (enExample)
EP (1) EP3341725B1 (enExample)
JP (2) JP6989927B2 (enExample)
CA (1) CA2994518C (enExample)
DK (1) DK3341725T3 (enExample)
ES (1) ES2890073T3 (enExample)
HU (1) HUE056054T2 (enExample)
PT (1) PT3341725T (enExample)
WO (1) WO2017033152A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3341725T (pt) 2015-08-25 2021-09-21 Prothena Biosciences Ltd Métodos para detetar alfa-sinucleína fosforilada
AU2017359944B2 (en) 2016-11-15 2024-07-18 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
US11237176B2 (en) 2016-12-02 2022-02-01 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
ES3008133T3 (en) 2016-12-16 2025-03-21 H Lundbeck As Agents, uses and methods
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3729088B1 (en) * 2017-12-21 2021-10-20 H. Lundbeck A/S Diagnosis and treatment of alpha-synucleinopathies
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020146497A1 (en) * 2019-01-09 2020-07-16 The Regents Of The University Of California An electrochemiluminescence elisa for ps129-a-synuclein
JP2023504699A (ja) * 2019-12-04 2023-02-06 エイシー イミューン ソシエテ アノニム 治療および診断のための新規な分子
CN112710850A (zh) * 2020-12-29 2021-04-27 苏州百志生物科技有限公司 一种检测人体液中α-突触核蛋白含量的试剂盒
WO2024163454A1 (en) * 2023-01-30 2024-08-08 The Regents Of The University Of California A duplex electrochemiluminescence immunoassay for total α-synuclein and ps129-α-synuclein

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DK0667959T3 (da) * 1992-10-26 2003-12-08 Elan Pharm Inc Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid
US5914241A (en) 1993-01-19 1999-06-22 Biosite Diagnostics, Inc. Assays and kits for detecting analytes in the presence of cross-reacting substances
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5965375A (en) 1997-04-04 1999-10-12 Biosite Diagnostics Diagnostic tests and kits for Clostridium difficile
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
RU2014105172A (ru) * 2011-07-13 2015-08-20 Мерк Шарп И Доум Корп. Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения
PT3341725T (pt) 2015-08-25 2021-09-21 Prothena Biosciences Ltd Métodos para detetar alfa-sinucleína fosforilada

Also Published As

Publication number Publication date
US20210165000A1 (en) 2021-06-03
EP3341725A1 (en) 2018-07-04
US20230228772A1 (en) 2023-07-20
HK1257103A1 (en) 2019-10-11
ES2890073T3 (es) 2022-01-17
CA2994518A1 (en) 2017-03-02
JP7244949B2 (ja) 2023-03-23
JP2021193374A (ja) 2021-12-23
JP2018526642A (ja) 2018-09-13
US20170192017A1 (en) 2017-07-06
PT3341725T (pt) 2021-09-21
EP3341725B1 (en) 2021-08-18
DK3341725T3 (da) 2021-09-06
JP6989927B2 (ja) 2022-02-03
HUE056054T2 (hu) 2022-02-28
WO2017033152A1 (en) 2017-03-02
US10852309B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
CA2994518C (en) METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN
MA46814A1 (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
CO2019005842A2 (es) Anticuerpos anti-pd-l1 radiomarcados para imágenes de inmuno-pet
WO2018084506A3 (ko) 가도리니움 화합물을 반응시킨 암석 시료의 전자현미경 이미지를 활용한 공극률 측정방법
EP3759145A4 (en) Diagnostic methods using anti-muc1* antibodies
EP3526559A4 (en) VIBRATION SENSOR FOR LIQUID LEAK DETECTION
MA38632A1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
EP3408671C0 (en) METHOD FOR TESTING T-CELL DEPENDENT BISPECIFIC ANTIBODIES
FR3071920B1 (fr) Detection et caracterisation ameliorees d'anomalies dans un continuum d'eau
SG10201906750XA (en) Assays for detecting the presence or amount of an anti-drug antibody
JP2018169350A5 (enExample)
FR3044312B1 (fr) Polypeptides mutes de hev et leur utilisation pour le dosage d'anticorps anti-hev
EA202191931A1 (ru) Способ характеризации видимых и/или невидимых частиц в биологических препаратах
SG10201906981TA (en) Methods and reagents for the assessment of gestational diabetes
MA39407A1 (fr) Compositions de cyclodextrine et de dérivés de budésonide et procédés associés
EP3904379A4 (en) HUMAN PARAINFLUENCE VIRUS (PIV) L-PROTEIN BINDING MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHODS AND KIT FOR THE DETECTION OF PIV
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EA201890740A1 (ru) Способ количественного определения чистоты образцов с невидимыми невооруженным глазом частицами
PL412309A1 (pl) Sposób wykrywania i/lub identyfikacji pierwotniaków z rodzaju Babesia, starter do zastosowania w tym sposobie oraz zestaw do stosowania w sposobach diagnostyki objawowej i bezobjawowej babeszjozy
JP2017538786A5 (enExample)
FR3087205B1 (fr) Compositions et procédés de détection d’acide nucléique à streptocoque de groupe B
JP2017012129A5 (enExample)
WO2015061475A8 (en) Compositions and methods for detection and discrimination of influenza viruses
EA202090630A1 (ru) Устройство для анализа и способ анализа
Sung et al. Stress intensity factor solutions for similar and dissimilar spot welds in lap-shear specimens under clamped loading conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812

EEER Examination request

Effective date: 20210812